Date: 2017-08-15
Type of information: Private placement
Company: Omeros (USA - Wn)
Investors:
Amount:
Funding type: private placement
Planned used:
- Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to funding research and development for its OMS721 programs and clinical trials, pre-clinical studies, manufacturing and other costs associated with advancing its product candidates toward Biologic License Application and New Drug Application submissions. Omeros may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own, and other capital expenditures.
Others:
- • On August 15, 2017, Omeros announced the pricing of its previously announced underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $22.75 per share, before deducting underwriting discounts and other estimated offering expenses. This bought deal offering is expected to close on or about August 18, 2017, subject to the satisfaction of customary closing conditions. In addition, Omeros has granted the underwriters a 30-day option to purchase up to 450,000 additional shares of its common stock.
- • On August 14, 2017, Omeros announced that it has commenced a registered underwritten public offering of 3,000,000 shares of its common stock. In addition, Omeros has granted the underwriter a 30-day option to purchase up to 450,000 additional shares of its common stock.
- Cantor Fitzgerald & Co. is acting as the bookrunner for the offering.
Therapeutic area:
Is general: Yes
